中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

44 records (took 0.022 seconds)

    SALTS OF DASATINIB IN AMORPHOUS FORM
    1.
    发明申请
    SALTS OF DASATINIB IN AMORPHOUS FORM 审中-公开
    非那西丁盐以非晶形式存在

    公开(公告)号：WO2015011119A2

    公开(公告)日：2015-01-29

    申请号：PCT/EP2014065674

    申请日：2014-07-22

    Applicant: BASF SE

    Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

    IPC: C07D417/12

    CPC classification number: C07D417/12 ,  C07C55/12 ,  C07D213/80 ,  C07D275/06

    Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

    Abstract translation: 本发明主要涉及达沙替尼的盐，其中盐为无定形形式。 本文所述的盐优选包含式1化合物的阳离子和选自戊二酸，烟酸和糖精的第二化合物的阴离子。 本发明还涉及包含这种盐的药物组合物。 此外，本发明涉及制备所述盐的方法。 本发明还涉及使用所述盐或药物组合物治疗疾病的几个方面。

    SALTS OF DASATINIB IN CRYSTALLINE FORM
    3.
    发明申请
    SALTS OF DASATINIB IN CRYSTALLINE FORM 审中-公开
    DASATINIB在结晶形式中的作用

    公开(公告)号：WO2015011120A3

    公开(公告)日：2015-04-16

    申请号：PCT/EP2014065675

    申请日：2014-07-22

    Applicant: BASF SE

    Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

    IPC: C07D417/12 ,  A61K31/506

    CPC classification number: C07D417/12 ,  C07B2200/13 ,  C07D275/06

    Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

    Abstract translation: 本发明主要涉及分子结晶物质，优选结晶形式的达沙替尼盐，其包含式1化合物，优选式1化合物的阳离子和选自戊二酸，烟酸 和糖精，优选其阴离子。 本发明还涉及包含这种物质的药物组合物。 此外，本发明涉及制备所述物质的方法。 本发明还涉及使用所述物质或药物组合物治疗疾病的若干方面。

    PANEL DE LUZ DIURNA
    4.
    发明专利
    PANEL DE LUZ DIURNA 未知

    公开(公告)号：ES1221619U

    公开(公告)日：2018-12-07

    申请号：ES201890011

    申请日：2017-11-02

    Applicant: BASF SE ,  BASF CHINA CO LTD

    Inventor： GARRIDO SEGURA CRISTOBAL ,  HINTERMANN TOBIAS ,  KOSTRO ANDRE ,  VETTER TATJANA

    IPC: F21V8/00 ,  F21S11/00

    Abstract: 1. Sistema de iluminación diurna que comprende un tubo (801) de transporte de luz para integración horizontal en un edificio o vehículo, el tubo de transporte de luz tiene un extremo delantero y un extremo posterior, en el que el extremo trasero está sellado, las paredes interiores incluyen la parte posterior el extremo está equipado con una capa (808) reflectante, y una pared lateral contiene una o más aberturas, cada una de las cuales está sellada con una luminaria (807), caracterizado porque la capa (808) reflectante proporciona una reflectividad, promediada en todos los ángulos de incidencia, polarizaciones y longitudes de onda del rango visible, del 96.5% o más, y el extremo frontal abierto es adecuado para unirse al lado interno de un plano elemento (800) de fachada transparente del edificio o elemento de pared del vehículo, o el extremo frontal está sellado a una placa (800) frontal transparente adecuada para su integración en la fachada del edificio o la pared del vehículo.

    Salts of Dasatinib in crystalline form
    8.
    发明专利
    Salts of Dasatinib in crystalline form 未知

    公开(公告)号：AU2014295144A1

    公开(公告)日：2016-02-11

    申请号：AU2014295144

    申请日：2014-07-22

    Applicant: BASF SE

    Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

    IPC: C07D417/12 ,  A61K31/506

    Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Patent Agency Ranking